Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
USPH vs ENSG vs NHC vs CCRN vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
USPH vs ENSG vs NHC vs CCRN vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $903M | $10.02B | $2.95B | $426M | $1.65B |
| Revenue (TTM) | $695M | $5.27B | $1.51B | $761M | $1.84B |
| Net Income (TTM) | $11M | $363M | $124M | $-99M | $59M |
| Gross Margin | 22.0% | 15.2% | 29.8% | 18.2% | 13.3% |
| Operating Margin | 12.5% | 8.5% | 8.6% | -0.9% | 3.0% |
| Forward P/E | 20.9x | 22.7x | 23.7x | 156.2x | 21.3x |
| Total Debt | $426M | $4.15B | $87M | $2M | $25M |
| Cash & Equiv. | $36M | $504M | $111M | $109M | $161M |
USPH vs ENSG vs NHC vs CCRN vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| U.S. Physical Thera… (USPH) | 100 | 80.0 | -20.0% |
| The Ensign Group, I… (ENSG) | 100 | 392.2 | +292.2% |
| National HealthCare… (NHC) | 100 | 281.5 | +181.5% |
| Cross Country Healt… (CCRN) | 100 | 217.1 | +117.1% |
| Healthcare Services… (HCSG) | 100 | 96.4 | -3.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: USPH vs ENSG vs NHC vs CCRN vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
USPH is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (20.9x vs 21.3x)
- 3.0% yield, 5-year raise streak, vs NHC's 1.3%, (2 stocks pay no dividend)
ENSG ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.4% 10Y total return vs NHC's 225.1%
- 18.7% revenue growth vs CCRN's -21.6%
- Beta 0.38 vs HCSG's 1.14
NHC carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 12 yrs, beta 0.63, yield 1.3%
- PEG 1.03 vs ENSG's 1.64
- Beta 0.63, yield 1.3%, current ratio 1.77x
- 8.2% margin vs CCRN's -13.0%
CCRN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.68, Low D/E 0.7%, current ratio 3.78x
Among these 5 stocks, HCSG doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (20.9x vs 21.3x) | |
| Quality / Margins | 8.2% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.38 vs HCSG's 1.14 | |
| Dividends | 3.0% yield, 5-year raise streak, vs NHC's 1.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +102.2% vs USPH's -13.8% | |
| Efficiency (ROA) | 10.6% ROA vs CCRN's -19.8%, ROIC 9.9% vs -0.9% |
USPH vs ENSG vs NHC vs CCRN vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
USPH vs ENSG vs NHC vs CCRN vs HCSG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NHC leads in 3 of 6 categories
USPH leads 0 • ENSG leads 0 • CCRN leads 0 • HCSG leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NHC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ENSG is the larger business by revenue, generating $5.3B annually — 7.6x USPH's $695M. NHC is the more profitable business, keeping 8.2% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $695M | $5.3B | $1.5B | $761M | $1.8B |
| EBITDAEarnings before interest/tax | $109M | $558M | $175M | $9M | $72M |
| Net IncomeAfter-tax profit | $11M | $363M | $124M | -$99M | $59M |
| Free Cash FlowCash after capex | $67M | $406M | $168M | $40M | $139M |
| Gross MarginGross profit ÷ Revenue | +22.0% | +15.2% | +29.8% | +18.2% | +13.3% |
| Operating MarginEBIT ÷ Revenue | +12.5% | +8.5% | +8.6% | -0.9% | +3.0% |
| Net MarginNet income ÷ Revenue | +1.5% | +6.9% | +8.2% | -13.0% | +3.2% |
| FCF MarginFCF ÷ Revenue | +9.6% | +7.7% | +11.1% | +5.2% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.7% | +18.4% | -1.0% | -100.0% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -115.0% | +21.9% | +9.7% | -6.0% | +175.0% |
Valuation Metrics
Evenly matched — USPH and CCRN each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 24.6x trailing earnings, NHC trades at a 41% valuation discount to USPH's 41.8x P/E. Adjusting for growth (PEG ratio), NHC offers better value at 1.07x vs ENSG's 2.13x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $903M | $10.0B | $2.9B | $426M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $13.7B | $2.9B | $320M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 41.75x | 29.36x | 24.62x | -4.50x | 28.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.91x | 22.68x | 23.69x | 156.16x | 21.30x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.13x | 1.07x | — | — |
| EV / EBITDAEnterprise value multiple | 12.58x | 25.40x | 15.51x | 23.97x | 23.20x |
| Price / SalesMarket cap ÷ Revenue | 1.16x | 1.98x | 1.95x | 0.40x | 0.90x |
| Price / BookPrice ÷ Book value/share | 1.17x | 4.52x | 2.75x | 1.32x | 3.30x |
| Price / FCFMarket cap ÷ FCF | 14.81x | 27.02x | 19.82x | 10.63x | 11.87x |
Profitability & Efficiency
NHC leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), NHC scores 7/9 vs ENSG's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +1.4% | +16.6% | +11.6% | -27.1% | +11.8% |
| ROA (TTM)Return on assets | +0.9% | +6.8% | +10.6% | -19.8% | +7.3% |
| ROICReturn on invested capital | +5.6% | +7.0% | +9.9% | -0.9% | +9.0% |
| ROCEReturn on capital employed | +7.6% | +10.2% | +11.2% | -0.8% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 7 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.55x | 1.86x | 0.08x | 0.01x | 0.05x |
| Net DebtTotal debt minus cash | $390M | $3.7B | -$24M | -$106M | -$136M |
| Cash & Equiv.Liquid assets | $36M | $504M | $111M | $109M | $161M |
| Total DebtShort + long-term debt | $426M | $4.2B | $87M | $2M | $25M |
| Interest CoverageEBIT ÷ Interest expense | 8.24x | 88.33x | 61.40x | -1.39x | 33.02x |
Total Returns (Dividends Reinvested)
NHC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NHC five years ago would be worth $28,418 today (with dividends reinvested), compared to $5,735 for USPH. Over the past 12 months, NHC leads with a +102.2% total return vs USPH's -13.8%. The 3-year compound annual growth rate (CAGR) favors NHC at 51.1% vs CCRN's -17.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -24.3% | -1.4% | +45.3% | +63.5% | +32.9% |
| 1-Year ReturnPast 12 months | -13.8% | +26.0% | +102.2% | -5.2% | +60.7% |
| 3-Year ReturnCumulative with dividends | -43.5% | +85.9% | +245.3% | -43.9% | +53.6% |
| 5-Year ReturnCumulative with dividends | -42.6% | +105.6% | +184.2% | -23.1% | -17.7% |
| 10-Year ReturnCumulative with dividends | +23.1% | +738.2% | +225.1% | -9.9% | -24.9% |
| CAGR (3Y)Annualised 3-year return | -17.3% | +23.0% | +51.1% | -17.5% | +15.4% |
Risk & Volatility
Evenly matched — ENSG and NHC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ENSG is the less volatile stock with a 0.38 beta — it tends to amplify market swings less than HCSG's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NHC currently trades 99.4% from its 52-week high vs USPH's 63.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 0.38x | 0.63x | 0.68x | 1.14x |
| 52-Week HighHighest price in past year | $93.50 | $218.00 | $189.95 | $14.99 | $24.39 |
| 52-Week LowLowest price in past year | $58.19 | $134.68 | $93.54 | $7.43 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +63.4% | +78.6% | +99.4% | +87.9% | +94.5% |
| RSI (14)Momentum oscillator 0–100 | 19.9 | 22.0 | 53.4 | 78.8 | 63.2 |
| Avg Volume (50D)Average daily shares traded | 167K | 364K | 118K | 578K | 672K |
Analyst Outlook
Evenly matched — USPH and HCSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: USPH as "Buy", ENSG as "Buy", CCRN as "Hold", HCSG as "Hold". Consensus price targets imply 72.0% upside for USPH (target: $102) vs -19.5% for CCRN (target: $11). For income investors, USPH offers the higher dividend yield at 3.04% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | — | Hold | Hold |
| Price TargetConsensus 12-month target | $102.00 | $222.33 | — | $10.61 | $24.50 |
| # AnalystsCovering analysts | 13 | 13 | — | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | +3.0% | +0.1% | +1.3% | — | — |
| Dividend StreakConsecutive years of raises | 5 | 12 | 12 | 1 | 20 |
| Dividend / ShareAnnual DPS | $1.80 | $0.24 | $2.47 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +0.2% | +0.5% | +1.6% | +3.7% |
NHC leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
USPH vs ENSG vs NHC vs CCRN vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is USPH or ENSG or NHC or CCRN or HCSG a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). National HealthCare Corporation (NHC) offers the better valuation at 24. 6x trailing P/E (23. 7x forward), making it the more compelling value choice. Analysts rate U. S. Physical Therapy, Inc. (USPH) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — USPH or ENSG or NHC or CCRN or HCSG?
On trailing P/E, National HealthCare Corporation (NHC) is the cheapest at 24.
6x versus U. S. Physical Therapy, Inc. at 41. 8x. On forward P/E, U. S. Physical Therapy, Inc. is actually cheaper at 20. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: National HealthCare Corporation wins at 1. 03x versus The Ensign Group, Inc. 's 1. 64x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — USPH or ENSG or NHC or CCRN or HCSG?
Over the past 5 years, National HealthCare Corporation (NHC) delivered a total return of +184.
2%, compared to -42. 6% for U. S. Physical Therapy, Inc. (USPH). Over 10 years, the gap is even starker: ENSG returned +738. 2% versus HCSG's -24. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — USPH or ENSG or NHC or CCRN or HCSG?
By beta (market sensitivity over 5 years), The Ensign Group, Inc.
(ENSG) is the lower-risk stock at 0. 38β versus Healthcare Services Group, Inc. 's 1. 14β — meaning HCSG is approximately 200% more volatile than ENSG relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — USPH or ENSG or NHC or CCRN or HCSG?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — USPH or ENSG or NHC or CCRN or HCSG?
National HealthCare Corporation (NHC) is the more profitable company, earning 7.
9% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 7. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USPH leads at 10. 3% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — NHC leads at 67. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is USPH or ENSG or NHC or CCRN or HCSG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, National HealthCare Corporation (NHC) is the more undervalued stock at a PEG of 1. 03x versus The Ensign Group, Inc. 's 1. 64x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, U. S. Physical Therapy, Inc. (USPH) trades at 20. 9x forward P/E versus 156. 2x for Cross Country Healthcare, Inc. — 135. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 0% to $102. 00.
08Which pays a better dividend — USPH or ENSG or NHC or CCRN or HCSG?
In this comparison, USPH (3.
0% yield), NHC (1. 3% yield), ENSG (0. 1% yield) pay a dividend. CCRN, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is USPH or ENSG or NHC or CCRN or HCSG better for a retirement portfolio?
For long-horizon retirement investors, The Ensign Group, Inc.
(ENSG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 38), +738. 2% 10Y return). Both have compounded well over 10 years (ENSG: +738. 2%, HCSG: -24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between USPH and ENSG and NHC and CCRN and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: USPH is a small-cap high-growth stock; ENSG is a mid-cap high-growth stock; NHC is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock. USPH, NHC pay a dividend while ENSG, CCRN, HCSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.